Updates on the Treatment of Lupus Nephritis
Open Access
- 1 December 2010
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 21 (12), 2028-2035
- https://doi.org/10.1681/asn.2010050472
Abstract
The treatment of lupus nephritis has changed significantly over the past decade in large part because of data from well-conducted randomized clinical trials. The concept of two phases of therapy—induction and maintenance—is widely accepted. The histopathologic classification of lupus nephritis continues to guide therapy, and treatment for all major classes of lupus nephritis has seen some shift in management during this time. New regimens using lower doses and shorter treatment durations of intravenous cyclophosphamide have been advanced to reduce toxicity without sacrificing efficacy of therapy. Mycophenolate mofetil has emerged as a viable alternative to cyclophosphamide for induction therapy of both proliferative and membranous lupus nephritis. Combination induction treatment with multiple agents has also been successful. Large controlled trials using mycophenolate mofetil and azathioprine for maintenance therapy have been performed. Here, we review recent additions to the growing body of literature on how to most effectively treat lupus nephritis with the least amount of toxicity. We discuss new treatment strategies currently being explored in clinical trials.Keywords
This publication has 64 references indexed in Scilit:
- Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysisLupus, 2010
- Effect of long‐term belimumab treatment on b cells in systemic lupus erythematosus: Extension of a phase II, double‐blind, placebo‐controlled, dose‐ranging studyArthritis & Rheumatism, 2009
- A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosusArthritis Care & Research, 2009
- Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus NephritisJournal of the American Society of Nephrology, 2009
- Randomized, Controlled Trial of Prednisone, Cyclophosphamide, and Cyclosporine in Lupus Membranous NephropathyJournal of the American Society of Nephrology, 2009
- Rituximab in Severe Lupus NephritisClinical Journal of the American Society of Nephrology, 2009
- Successful Treatment of Class V+IV Lupus Nephritis with Multitarget TherapyJournal of the American Society of Nephrology, 2008
- Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosusArthritis Research & Therapy, 2008
- Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohortRheumatology, 2008
- The role of aldosterone blockade in murine lupus nephritisArthritis Research & Therapy, 2008